LIPIODOL
Drug
GUERBET LLC
Total Payments
$2.0M
Transactions
255
Doctors
56
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $665,307 | 109 | 30 |
| 2023 | $7,150 | 1 | 1 |
| 2022 | $45,362 | 13 | 9 |
| 2021 | $1.1M | 7 | 0 |
| 2017 | $253,639 | 125 | 29 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.8M | 24 | 89.5% |
| Consulting Fee | $113,382 | 32 | 5.6% |
| Travel and Lodging | $77,308 | 89 | 3.8% |
| Food and Beverage | $20,003 | 108 | 1.0% |
| Grant | $4,000 | 1 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $500.00 | 1 | 0.0% |
Payments by Type
Research
$1.8M
24 transactions
General
$215,193
231 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Randomized Embolization Trial for NeuroEndoccrine Tumor Metastases to the Liver (RETNET): A randomized trial to compare hepatic progression free survival following bland emobilization, lipiodol chemoembolization, and drug-eluting bead chemoembolization | GUERBET LLC | $684,154 | 0 |
| Embolotherapy Using the SeQure Antireflux Catheter: Assessment of Targeted Drug Delivery in a Porcine Liver Tumor Embolization Model | GUERBET LLC | $237,583 | 0 |
| Chemoembolization of Uveal Melanoma Hepatic mestastases using 300mg of BCNU Dissolved in Lipiodol followed by Gelfoam Embolization | GUERBET LLC | $99,204 | 0 |
| Safety and Efficacy of Convenetional TACE Followed by Percutaneous Thermal Ablation of Hepatocellular Carcinoma: 10 Years Experience in the Medical Univerisity of South Carolina | GUERBET LLC | $79,997 | 0 |
| In Situ Imaging of Blood Oxygenation Following Lipiodol TACE | GUERBET LLC | $57,429 | 0 |
| Can Quantitative MRI after cTACE Help Predict Survival | GUERBET LLC | $53,697 | 0 |
| Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver (RETNET) | GUERBET LLC | $48,336 | 0 |
| Single-Center Long-Term Outcomes of conventional Lipiodol Chemoembolization (cTACE) of Hepatocellular Carcinoma (HCC) | GUERBET LLC | $35,984 | 0 |
| Degree and Duration of Lipiodol Retention in Hepatocellular Carcinoma (HCC) after Intra-arterial Delivery for Chemoembolization and Correlation with Residual Enhancement on Post Chemoembolization CT: A Retrospective Study | GUERBET LLC | $35,585 | 0 |
| Therapeutic Effect of Sonographic Hysterosalpingography: Oil vs Water Based Media: The SHOW Pilot Trial | GUERBET LLC | $11,547 | 0 |
| Can Quantitative MRI after cTACE Help Predict Survival? | GUERBET LLC | $7,086 | 0 |
Top Doctors Receiving Payments for LIPIODOL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $1.8M | 25 |
| , MD | Diagnostic Radiology | Philadelphia, PA | $57,691 | 11 |
| , MD | Vascular & Interventional Radiology | Philadelphia, PA | $19,430 | 14 |
| , MD | Vascular & Interventional Radiology | Charleston, SC | $12,634 | 4 |
| , MD | Diagnostic Radiology | Milwaukee, WI | $11,708 | 7 |
| , M.D | Diagnostic Radiology | Houston, TX | $10,645 | 6 |
| , M.D | Diagnostic Radiology | San Antonio, TX | $10,000 | 3 |
| , MD | Vascular & Interventional Radiology | San Antonio, TX | $10,000 | 3 |
| , M.D | Vascular & Interventional Radiology | New Haven, CT | $9,894 | 1 |
| , M.D | Vascular & Interventional Radiology | Salt Lake City, UT | $4,706 | 1 |
| , MD | Vascular & Interventional Radiology | Chicago, IL | $4,678 | 6 |
| , M.D | Diagnostic Radiology | New York, NY | $4,400 | 1 |
| , MD | Vascular & Interventional Radiology | Orange, CA | $3,645 | 11 |
| , M.D | Diagnostic Radiology | Boston, MA | $3,210 | 9 |
| , M.D | Diagnostic Radiology | San Francisco, CA | $3,208 | 11 |
| , MD, PHD | Vascular & Interventional Radiology | New York, NY | $2,687 | 10 |
| , MD | Diagnostic Radiology | Iowa City, IA | $2,539 | 2 |
| , M.D | Diagnostic Radiology | Houston, TX | $2,411 | 8 |
| , MD | Surgery | Philadelphia, PA | $2,219 | 9 |
| , M.D | Neuroradiology | San Diego, CA | $1,986 | 5 |
| , M.D | Vascular & Interventional Radiology | Boston, MA | $1,985 | 5 |
| , M.D | Family Medicine | Largo, FL | $1,978 | 3 |
| , M.D., PH.D | Internal Medicine | San Diego, CA | $1,778 | 5 |
| , M.D., PH.D | Vascular & Interventional Radiology | San Francisco, CA | $1,672 | 5 |
| , MD | Diagnostic Radiology | Baltimore, MD | $1,671 | 5 |
Ad
Manufacturing Companies
- GUERBET LLC $2.0M
Product Information
- Type Drug
- Total Payments $2.0M
- Total Doctors 56
- Transactions 255
About LIPIODOL
LIPIODOL is a drug associated with $2.0M in payments to 56 healthcare providers, recorded across 255 transactions in the CMS Open Payments database. The primary manufacturer is GUERBET LLC.
Payment data is available from 2017 to 2024. In 2024, $665,307 was paid across 109 transactions to 30 doctors.
The most common payment nature for LIPIODOL is "Unspecified" ($1.8M, 89.5% of total).
LIPIODOL is associated with 11 research studies, including "Randomized Embolization Trial for NeuroEndoccrine Tumor Metastases to the Liver (RETNET): A randomized trial to compare hepatic progression free survival following bland emobilization, lipiodol chemoembolization, and drug-eluting bead chemoembolization" ($684,154).